Skip to main content

Table 2 Diagnostic performance indexes in assessing complete response (CR) according to RECIST criteria 1.1, using CESM and MRI, compared to histopathological assessment of surgical specimens (gold standard)

From: Contrast-enhanced spectral mammography in neoadjuvant chemotherapy monitoring: a comparison with breast magnetic resonance imaging

Assessment

 

RECIST 1.1

Hystopathology pCR

Hystopathology non-pCR (pPR, pSD, pPD)

 

CESM

CR

8

6

PPV 57% (CI 29–82%)

non-CR (PR, SD, PD)

0

32

NPV 100% (CI 90–100%)

 

Sensitivity 100% (CI 63–100%)

Specificity 84% (CI 69–94%)

 

MRI

CR

7

15

PPV 32% (CI 14–55%)

non-CR (PR, SD, PD)

1

23

NPV 96% (CI 79–100%)

 

Sensitivity 87% (CI 47–100%)

Specificity 60% (CI 43–76%)

 
  1. RECIST response evaluation criteria in solid tumors, CESM contrast-enhanced spectral mammography, MRI magnetic resonance imaging, pCR pathological complete response, pPR pathological partial response, pSD pathological stable disease, pPD pathological progressive disease, PR partial response, SD stable disease, PD progressive disease, PPV positive predictive value, NPV negative predictive value